CUTTING-EDGE TECHNOLOGY FOR THE ANIMAL HEALTH PROTECTION.

Our exclusive new Foot and Mouth Disease (FMD) Vaccine Plant meets the highest international production standards as the most modern installation in Latin America.

CDV

DIAGNOSIS AND VACCINES
FOR ANIMAL HEALTH

CDVac FMD Vaccine Production Plant

With a total investment of USD 40 million, CDV's FMD Vaccine Production Plant has been constructed to meet the strictest international quality standards, with cutting-edge equipment and a high degree of automatism. It spans over 4,700 sq.m. and has three independent sections that meet the OIE Biosafety level 4 and the Environmental, Health and Safety Regulation requirements.

The plant has a production capacity of over 40 million vaccine doses of bi-, tri- and quadrivalent composition, and is fit for handling local and exotic strains destined to the Argentine, regional or Asian markets in accordance with the regulatory requirements.

Through means of technology transfer, world-wide specialised counselling has been provided on the development of biotechnological processes, which has allowed for state-of-the-art CDV FMD vaccine manufacturing methods and highly-purified antigens.

The highly-qualified plant personnel has been trained by a crossdisciplinary team of professionals with a track record in complementary fields such as Biosafety, Production, Quality Control, Biotechnology and Processes.

The plant was certified in December 2017 and certified under GMP standards in 2019 and re-certified in 2023 by SENASA.

FMD Vaccine technical specifications

Antigenic composition	FMD virus types O1 Campos, A24 Cruzeiro, A Argentina 2001 and C3 Indaial in BHK cell cultures, inactivated with BEI and oil adjuvant.
Guidelines for use	Administered as a preventive measure against FMD, strictly following the regulations determined by SENASA (the National Service of Agri-Food Health and Quality) and other healthcare bodies in the countries where the vaccine is utilised.
Administration and doses	2 ml for bovines and 1 ml for swine and sheep. Subcutaneous or deep intramuscular use, behind the shoulder blades or in neck muscles. The vaccine induces active immunity for 6 months in primovaccinated animals less than 6 months old, and for 12 months in revaccinated animals.
Warning	Due to the adjuvant, local reactions might occur in the inoculation site that will disappear over time. Occasionally, anaphylactoid reactions might occur in sensitised animals, in which case short-acting corticosteroids should be applied.
Presentation	250 ml (125 doses); 100 ml (50 doses).
Conservation	Store at 2ºC to 8ºC. Do not freeze. During transportation, keep temperatures below 15ºC for up to 72 hours.

Recommendations

- Maintain the cold chain until administration, between 2ºC and 8ºC. Do not freeze.
- During vaccination, keep vaccines in the shade inside their cool boxes along with the refrigerants.
- Under the conditions described above, transportation time must not exceed 72 hours.
- Animals should be in a good state of health and nutrition, free from endo- and ectoparasites.
- Avoid stress in animals and allow them to rest for a minimum of two hours prior to vaccination.
- Shake the vial vigorously before loading into the syringe.
- Administering the vaccine in the upper third of the neck muscles, use a 20/20 needle for deep intramuscular injection or a 15/18 needle for subcutaneous use.
- Change the needle every 20/25 animals.

CDV

DIAGNOSIS AND VACCINES
FOR ANIMAL HEALTH

SCAN FOR MORE INFORMATION